178 related articles for article (PubMed ID: 2541133)
1. Quantitation of poliovirus antigens in inactivated viral vaccines by enzyme-linked immunosorbent assay using animal sera and monoclonal antibodies.
Singer C; Knauert F; Bushar G; Klutch M; Lundquist R; Quinnan GV
J Biol Stand; 1989 Apr; 17(2):137-50. PubMed ID: 2541133
[TBL] [Abstract][Full Text] [Related]
2. Quantitation of D antigen content in inactivated poliovirus vaccine derived from wild-type or sabin strains.
Sawyer LA; McInnis J; Albrecht P
Biologicals; 1993 Jun; 21(2):169-77. PubMed ID: 8297601
[TBL] [Abstract][Full Text] [Related]
3. Universal ELISA for quantification of D-antigen in inactivated poliovirus vaccines.
Kouiavskaia D; Puligedda RD; Dessain SK; Chumakov K
J Virol Methods; 2020 Feb; 276():113785. PubMed ID: 31765719
[TBL] [Abstract][Full Text] [Related]
4. [A monoclonal antibody panel for the intratypic differentiation of type-2 polioviruses].
Shyrobokov VP; Nikolaienko IV; Kopanytsia LV; Solohub VK; Ivanova OIe
Mikrobiol Z; 1997; 59(6):27-36. PubMed ID: 9511373
[TBL] [Abstract][Full Text] [Related]
5. Enzyme-linked immunosorbent assay for detection of poliovirus antigen and antibody.
Moynihan M; Ladefoged P; Mathiesen L
Dev Biol Stand; 1980; 46():203-6. PubMed ID: 6244998
[TBL] [Abstract][Full Text] [Related]
6. Induction of neutralizing antibodies by poliovirus capsid polypeptides VP1, VP2 and VP3.
van der Marel P; Hazendonk TG; Henneke MA; van Wezel AL
Vaccine; 1983 Dec; 1(1):17-22. PubMed ID: 6099638
[TBL] [Abstract][Full Text] [Related]
7. Deleterious effect of thimerosal on the potency of inactivated poliovirus vaccine.
Sawyer LA; McInnis J; Patel A; Horne AD; Albrecht P
Vaccine; 1994 Jul; 12(9):851-6. PubMed ID: 7526574
[TBL] [Abstract][Full Text] [Related]
8. [Application of ELISA for screening McAb against type III polioviruses and its antigenic analysis].
Gu FZ; Wang SH; Sun YY
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Oct; 7(5):359-63. PubMed ID: 2421926
[No Abstract] [Full Text] [Related]
9. Production and characterization of neutralizing monoclonal antibodies against poliovirus type 1, 2, and 3.
Payment P; Trudel M; Thibodeau L; Lecomte J
Can J Microbiol; 1989 May; 35(5):550-3. PubMed ID: 2545322
[TBL] [Abstract][Full Text] [Related]
10. Methods for the Quality Control of Inactivated Poliovirus Vaccines.
Wilton T
Methods Mol Biol; 2016; 1387():279-97. PubMed ID: 26983741
[TBL] [Abstract][Full Text] [Related]
11. Potency of wild-type or sabin trivalent inactivated poliovirus vaccine, by enzyme-linked immunosorbent assay using monoclonal antibiotics specific for each antigenic site.
Sawyer LA; Wood D; Ferguson M; Crainic R; Beuvery EC; McInnis J; Albrecht P
Biologicals; 1997 Sep; 25(3):299-306. PubMed ID: 9324998
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal antibodies to polioviruses. Production of specific monoclonal antibodies to the Sabin vaccine strains.
Osterhaus AD; van Wezel AL; van Steenis B; Drost GA; Hazendonk TG
Intervirology; 1981; 16(4):218-24. PubMed ID: 6177658
[TBL] [Abstract][Full Text] [Related]
13. Antigenic structure of poliovirus in inactivated vaccines.
Ferguson M; Wood DJ; Minor PD
J Gen Virol; 1993 Apr; 74 ( Pt 4)():685-90. PubMed ID: 7682250
[TBL] [Abstract][Full Text] [Related]
14. Nasopharyngeal secretory antibody response to poliovirus type 3 virion proteins exhibit different specificities after immunization with live or inactivated poliovirus vaccines.
Zhaori G; Sun M; Faden HS; Ogra PL
J Infect Dis; 1989 Jun; 159(6):1018-24. PubMed ID: 2470831
[TBL] [Abstract][Full Text] [Related]
15. Potency test of killed polio vaccines. Statistical analysis of test on chicken and preliminary results in combination with ELISA D-antigen determinations.
Larbaigt G; Moulin J; Souvras M; Gibelin N; Beranger G
Dev Biol Stand; 1981; 47():113-8. PubMed ID: 6262141
[TBL] [Abstract][Full Text] [Related]
16. A WHO Collaborative study on assays of the antigenic content of inactivated poliovirus vaccines.
Wood DJ; Heath AB; Sawyer LA
Biologicals; 1995 Mar; 23(1):83-94. PubMed ID: 7619442
[TBL] [Abstract][Full Text] [Related]
17. Neutralization epitopes on poliovirus type 3 particles: an analysis using monoclonal antibodies.
Ferguson M; Minor PD; Magrath DI; Qui YH; Spitz M; Schild GC
J Gen Virol; 1984 Jan; 65 ( Pt 1)():197-201. PubMed ID: 6198447
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of an enzyme-linked immunosorbent assay based on binding inhibition for type-specific quantification of poliovirus neutralization-relevant antibodies.
Hashido M; Horie H; Abe S; Doi Y; Hashizume S; Agboatwalla M; Isomura S; Nishio O; Hagiwara A; Inouye S
Microbiol Immunol; 1999; 43(1):73-7. PubMed ID: 10100750
[TBL] [Abstract][Full Text] [Related]
19. VaxArray immunoassay for the multiplexed quantification of poliovirus D-antigen.
Dawson ED; Taylor AW; Johnson JE; Hu T; McCormick C; Thomas KN; Gao RY; Wahid R; Mahmood K; Rowlen KL
J Immunol Methods; 2022 May; 504():113259. PubMed ID: 35314144
[TBL] [Abstract][Full Text] [Related]
20. Production and potential use of monoclonal antibodies against polio viruses.
Osterhaus AD; van Wezel AL; van Steenis G; Hazendonk AG; Drost G
Dev Biol Stand; 1981; 50():221-8. PubMed ID: 6281107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
